Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10903)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Nov 15, 2020 (publication date) through Jun 5, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zhang L, Xue S, Hou J, Chen G, Xu ZG. Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review. World J Diabetes 2020; 11(11): 553-566 [PMID: 33269066 DOI: 10.4239/wjd.v11.i11.553] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v11/i11/553.htm |
| Number | Citing Articles |
| 1 |
Giovanna Capolongo, Giovambattista Capasso, Davide Viggiano. A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter 2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets Hemodynamics. International Journal of Molecular Sciences 2022; 23(7): 3915 doi: 10.3390/ijms23073915
|
| 2 |
Alessio Mazzieri, Francesca Porcellati, Francesca Timio, Gianpaolo Reboldi. Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection. International Journal of Molecular Sciences 2024; 25(7): 3969 doi: 10.3390/ijms25073969
|
| 3 |
Shuhui Yang, Jiankun Deng, Xiaoxu Weng, Zhaojie Ma, Nie Lin, Yili Xiao, Rui Zuo, Yufei Hu, Canbin Zheng, Xiaoshan Zeng, Qimao Lin, Kaijian Hou. Reduced abundance of Fusobacterium signifies cardiovascular benefits of sodium glucose cotransporter 2 inhibitor in type 2 diabetes: a single arm clinical trial. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1600464
|
| 4 |
Olivia Blazek, George L. Bakris. A review of novel endothelin antagonists and overview of non-steroidal mineralocorticoid antagonists for treating resistant hypertension: An update. European Journal of Pharmacology 2024; 979: 176752 doi: 10.1016/j.ejphar.2024.176752
|
| 5 |
Noorain Ahmad, Harish Veerapalli, Chetan Reddy Lankala, Everardo E Castaneda, Afia Aziz, Amy G Rockferry, Pousette Hamid. Endothelin Receptor Antagonists as a Potential Treatment of Diabetic Nephropathy: A Systematic Review . Cureus 2021; doi: 10.7759/cureus.19325
|
| 6 |
Tzu-Hsien Chuang, Hsin-Yen Cho, Sheng-Nan Wu. The Evidence for Sparsentan-Mediated Inhibition of INa and IK(erg): Possibly Unlinked to Its Antagonism of Angiotensin II or Endothelin Type a Receptor. Biomedicines 2021; 10(1): 86 doi: 10.3390/biomedicines10010086
|
| 7 |
Semwal Bhupesh, Neha Chauhan, Verma Jyoti, Kumar Ankit, Singh Sonia, Singh Bhupendra. A Narrative Review of Signaling Pathway and Treatment Options for Diabetic Nephropathy. Current Molecular Medicine 2025; 25(2): 113 doi: 10.2174/1566524023666230727093911
|
| 8 |
Antony Sameh Mansour. Autoregulation: mediators and renin–angiotensin system in diseases and treatments. Future Journal of Pharmaceutical Sciences 2023; 9(1) doi: 10.1186/s43094-023-00482-4
|
| 9 |
Te-Ling Lu, Sheng-Nan Wu. Investigating the Impact of Selective Modulators on the Renin–Angiotensin–Aldosterone System: Unraveling Their Off-Target Perturbations of Transmembrane Ionic Currents. International Journal of Molecular Sciences 2023; 24(18): 14007 doi: 10.3390/ijms241814007
|
| 10 |
Katherine R. Tuttle, Rajiv Agarwal, Charles E. Alpers, George L. Bakris, Frank C. Brosius, Peter Kolkhof, Jaime Uribarri. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney International 2022; 102(2): 248 doi: 10.1016/j.kint.2022.05.012
|
| 11 |
Susan Miller, Walter Moos, Barbara Munk, Stephen Munk, Charles Hart, David Spellmeyer. Managing the Drug Discovery Process. 2023; : 207 doi: 10.1016/B978-0-12-824304-6.00001-8
|
| 12 |
Yang Yang, Gaosi Xu. Update on Pathogenesis of Glomerular Hyperfiltration in Early Diabetic Kidney Disease. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.872918
|
| 13 |
Kimio Watanabe, Emiko Sato, Eikan Mishima, Mariko Miyazaki, Tetsuhiro Tanaka. What’s New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances. International Journal of Molecular Sciences 2022; 24(1): 570 doi: 10.3390/ijms24010570
|
| 14 |
Wei Huang, Yi-Yuan Chen, Zi-Qi Li, Fang-Fang He, Chun Zhang. Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases. International Journal of Molecular Sciences 2022; 23(18): 10882 doi: 10.3390/ijms231810882
|
| 15 |
Zeinab H. El-Said, Sherihan I. Gouda, Hebatallah A. Mahgoub, S El_desouky, Neven A. Ebrahim. L- Thyroxine ameliorates renal function in thyroidectomized diabetic nephropathy rats through downregulation of TGF- β1, Ang II and ET-1 expression. Egyptian Journal of Basic and Applied Sciences 2023; 10(1): 632 doi: 10.1080/2314808X.2023.2248711
|